The BioPark Community is positioned to be a central hub of biotherapeutics development, and will serve as the home base for partner companies, offering modern office, lab and manufacturing space to support advanced therapy development.
Inno-Accelerator
Together with our partners, we are reimagining ways to build biotech companies & develop novel advanced therapies.
Our team has decades of experience as biotech company entrepreneurs globally & in China. We have assembled an international and deeply experienced team in development & commercialization of complex, advanced therapies. To further enable our partner companies to focus on core competencies, we offer a variety of enabling business support services such as Finance, HR, and IT management, and more.
We offer partner companies access to a complete suite of technologies for advanced biologic therapies, including modified & unmodified cell therapies, gene therapies, RNA medicines & vaccines, and protein drugs.
Small & mid-size biotech companies can leverage the scale & expertise that is often difficult to build on their own. Our world class development & manufacturing facilities serve end-to-end needs of partner companies for global markets, including preclinical, clinical & commercial supply.
With a track record accessing capital, we are positioned to support partner company financing and flexibility invest in equity, co-development or other partnership models. Our partner companies can limit capital investment in manufacturing & equipment, maximizing resources to advance their programs through the development life cycle.
| Company | Mayflower Bioventures | Sirnaomics | Hibiscus Biotechnology |
|---|---|---|---|
| Location | US | Rockville, MD | US | Gaithersburg, MD Suzhou, China | US | Rockville, MD |
| Focus |
 Cell & Gene Therapies
|
 RNA Therapeutics
|
Cell & Gene Therapies
|
Innoforce’s BioPark Community, currently under development,
is strategically located in Hangzhou, China, just one-hour by high-speed train from Shanghai.
CAMPUS DESIGN
The entire campus will include 11 buildings over 1.9 million square feet, becoming one of the largest pharma research, development and manufacturing facilities in China. The first phase of the Innoforce campus in Hangzhou will cover 21 acres.